skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
FOLFIRI-Bevacizumab Regimen (Code C63608)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: FOLFIRI-Bevacizumab Regimen

Definition: A chemoimmunotherapy regimen consisting of leucovorin, fluorouracil, and bevacizumab used for as an initial treatment for advanced-stage metastatic colorectal cancer.

NCI-GLOSS Definition: A chemotherapy combination used as an initial treatment of colorectal cancer that has spread. It includes the drugs leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and bevacizumab.

Display Name: FOLFIRI-Bevacizumab Regimen

Label: FOLFIRI-Bevacizumab Regimen

NCI Thesaurus Code: C63608 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1880657  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
FOLFIRI-Avastin Regimen
FOLFIRI-Avastin regimen
FOLFIRI-Bevacizumab Regimen
FOLFIRI-bevacizumab regimen
Folinic Acid-Fluorouracil-Irinotecan-Bevacizumab Regimen

External Source Codes: 
PDQ Closed Trial Search ID 657060
PDQ Open Trial Search ID 657060 (check for NCI PDQ open clinical trial info)
UMLS CUI C1880657

Other Properties:
     Name Value (qualifiers indented underneath)
code C63608
Contributing_Source CTRP
DesignNote Source: NCCN Guidelines and PDQ
Legacy_Concept_Name FOLFIRI-Bevacizumab_Regimen
Semantic_Type Therapeutic or Preventive Procedure

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom